Edematous Fibrosclerotic Panniculopathy Clinical Trial
Official title:
A Phase 1, Open-Label Study to Assess the Safety and Pharmacokinetics of a Single Dose of CCH (3.36 mg) in Subjects With Edematous Fibrosclerotic Panniculopathy
This study will evaluate the safety and Pharmacokinetics (PK) of a single 3.36-mg dose of
Collagenase Clostridium Histolyticum (CCH) in 4 quadrants concurrently, in subjects with
Edematous fibrosclerotic panniculopathy (EFP).
This study will provide insight to the PK profile and safety of concurrent subcutaneous
injections of CCH 0.84 mg/quadrant into 4 quadrants.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02942160 -
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
|
Phase 2 | |
| Completed |
NCT04580303 -
CCH Treatment of Cellulite in the Presence of Dermal Laxity With Comparison Between Two (2) Different Injection Techniques
|
Phase 2 | |
| Completed |
NCT03329989 -
Safety and Effectiveness of EN3835 in the Treatment of EFP in Women
|
Phase 2 | |
| Completed |
NCT04381117 -
Long-term Durability Study of Collagenase Clostridium Histolyticum (CCH)
|
||
| Completed |
NCT03893890 -
Durability and Safety of EN3835 in the Treatment of EFP (Cellulite) in Women
|
||
| Completed |
NCT05419505 -
Study of Different Interventions to Reduce Bruising Following CCH-Aaes Treatment for Cellulite of the Buttocks
|
Phase 2 | |
| Completed |
NCT05249257 -
Durability and Safety of CCH With Two Different Injection Techniques in Cellulite With Laxity
|
||
| Completed |
NCT01518907 -
The Safety, Effectiveness, and Pharmacokinetics of AA4500 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
|
Phase 1 | |
| Completed |
NCT02724644 -
EN3835 for the Treatment of Edematous Fibrosclerotic Panniculopathy (Commonly Known as Cellulite)
|
Phase 2 | |
| Completed |
NCT03526549 -
Long-Term Study of EN3835 (CCH-aaes) in Edematous Fibrosclerotic Panniculopathy (Cellulite)
|
Phase 3 |